ResearcherInstitut za onkologiju i radiologiju SrbijeActive in the last 2 years

Tatjana Srdić-Rajić

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9840-6970; OpenAlex author ID A5049064278, A5128650635. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2024: 1 paper · 2025: none · 2026: 1 paper

Papers 2

Repurposing Rilmenidine as a Potential Antimetastatic Therapy Targeting Nischarin in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells15111032 ↗
Unveiling the 4-aminoquinoline derivatives as potent agents against pancreatic ductal adenocarcinoma (PDAC) cell lines. Last author DOI 10.1016/j.cbi.2024.111281 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Kristina Živić · 1 shared paper, 2026 · strength 0.33
- Paper Repurposing Rilmenidine as a Potential Antimetastatic Therapy Targeting Nischarin in Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cells15111032 ↗
Jelena Grahovac · 1 shared paper, 2026 · strength 0.33
- Paper Repurposing Rilmenidine as a Potential Antimetastatic Therapy Targeting Nischarin in Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cells15111032 ↗
Marija Živanović · 1 shared paper, 2024 · strength 0.24
- Paper Unveiling the 4-aminoquinoline derivatives as potent agents against pancreatic ductal adenocarcinoma (PDAC) cell lines. DOI 10.1016/j.cbi.2024.111281 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.